Article
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
European urology - 1 Jan 2018
Borgmann Hendrik, Lallous Nada, Ozistanbullu Deniz, Beraldi Eliana, Paul Naman, Dalal Kush, Fazli Ladan, Haferkamp Axel, Lejeune Pascale, Cherkasov Artem, Gleave Martin E
Abstract excerpt
Darolutamide (ODM-201) is a novel androgen receptor (AR) antagonist with a chemical structure distinctly different from currently approved AR antagonists that targets both wild-type and mutated ligand binding domain variants to inhibit AR nuclear translocation. Here, we evaluate the activity of darolutamide in enzalutamide-resistant castration resistant prostate cancer (CRPC) as well as in AR mutants detected in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.